Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study

Do Hyun Park · with The Cleveland Clinic, University of Colorado, Denver · NCT07030348

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 19+ · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
263
US sites recruiting
2
Study start
January 2, 2024
Record last updated
June 22, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Purpose Pancreatic cancer is the fourth leading cancer-related mortality disease in the United States, with a five-year survival rate of 11%, and only 10 15% of all pancreatic cancer patients are operable or borderline operable.

Therefore, there is an unmet need for early diagnosis of pancreatic cancer; however, biomarkers related to this are not well understood. This study aims to identify biomarkers for the early diagnosis of pancreatic cancer through duodenal pancreatic juice, which can be easily obtained through an endoscopy.

Conditions: Pancreatic Cancers; Pancreatic Diseases

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

Among the patients requiring gastro-duodenal endoscopy, endoscopic ultrasound, or ERCP for medical purposes, the pancreatic cancer group should meet the criteria numbered 1, 2, and either 3 or 4.

  • Be at least 19 years old.
  • Have completed the informed consent for planned upper endoscopy, endoscopic ultrasound, or endoscopic retrograde cholangiopancreatography before the duodenal fluid collection.
  • A biopsy with proven stage I-IV pancreatic ductal adenocarcinoma (PDAC).
  • Suspected pancreatic cancer on imaging and scheduled for an endoscopic ultrasound-guided pancreatic biopsy.

The non-pancreatic cancer group should meet the criteria numbered 1, 2, and either 3 or 4.

  • Be at least 19 years old.
  • Have completed the informed consent for planned upper endoscopy, endoscopic ultrasound, or endoscopic retrograde cholangiopancreatography before the duodenal fluid collection.
  • Patients with pancreatic cystic tumors or patients with acute or chronic pancreatitis.
  • No evidence of a pancreatic disease.

Exclusion Criteria

The exclusion criteria for the pancreatic cancer and the non-pancreatic cancer groups will be:

  • Innate or post-surgical anatomy that precludes direct sampling of duodenal fluid.
  • Hemodynamically unstable and unable to have an endoscopy performed.
  • A large amount of ascites fluid that is not controlled and unable to have an endoscopy performed.
  • A coagulation disorder that cannot be corrected and unable to have an endoscopy performed.

Recruiting US locations

Study contacts (from the official record)

  • HyeJin Song, CRC · +82-2-2045-3825 · asangicrc@gmail.com
All healthy volunteers studies in Colorado →
Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based… (NCT07030348) | Bored Studies